Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action. Methods: Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n=662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35). Logistic regression analysis with remission as the dependent variable and treatment arm-by-BMI category interaction as the primary independent variable was used to evaluate if BMI differentially predicted response to escitalopram (SSRI) monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination, after controlling for gender and baseline depression severity. Results: Remission rates among the three treatment arms differed on the basis of pre-treatment BMI (chi-square=12.80, degrees of freedom=6, p=0.046). Normal- or under-weight participants were less likely to remit with the bupropion-SSRI combination (26.8%) than SSRI monotherapy (37.3%, number needed to treat or NNT=9.5) or venlafaxine-mirtazapine combination (44.4%, NNT=5.7). Conversely, obese II+ participants were more likely to remit with bupropion-SSRI (47.4%) than SSRI monotherapy (28.6%, NNT=5.3) or venlafaxine-mirtazapine combination (37.7%, NNT=10.3). Remission rates did not differ among overweight and obese I participants. Limitations: Secondary analysis, higher rates of obesity than the general population. Conclusions: Antidepressant selection in clinical practice can be personalized with BMI measurements. Bupropion-SSRI combination should be avoided in normal- or under-weight depressed outpatients as compared to SSRI monotherapy and venlafaxine-mirtazapine combination and preferred in those with BMI≥35.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“This results in a trial-and-error approach, often necessitating multiple attempts to attain adequate symptomatic control (Rush et al., 2006).”
BackgroundSelf-citationTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“In all three treatment arms, participants were treated using measurement-based care (MBC) approach (Trivedi et al., 2006) where dosage adjustments were based on symptom severity and side-effect, and medications were administered using two types of pills in single-blind fashion(Rush et al.”
MethodSelf-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“Also at baseline and at all treatment visits, participants filled out 16-item Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) scale (Rush et al., 2003) which was the primary depression symptom severity outcome measure in the CO-MED trial.”
MethodSelf-citationThase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Jha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T., Grannemann, B., Soyombo, A., Mayes, T. L., Rush, A. J., & Trivedi, M. H. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.01.023 · Cited by 206
Self-citationDepression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial
Arnow, B. A., Blasey, C., Williams, L. M., Palmer, D. M., Rekshan, W., Schatzberg, A. F., Etkin, A., Kulkarni, J., Luther, J. F., & Rush, A. J. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14020181 · Cited by 175 · cited 1×
“, 2012), and atypical or melancholic features (Arnow et al., 2015), have failed to guide selection between presently available antidepressant medications.”
BackgroundFriedman, E. S., Davis, L. L., Zisook, S., Wisniewski, S. R., Trivedi, M. H., Fava, M., & Rush, A. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.010 · Cited by 81
Self-citationJha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T. L., Mayes, T. L., & Trivedi, M. H. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.005 · Cited by 79
Self-citationToups, M. S. P., Myers, A. K., Wisniewski, S. R., Kurian, B., Morris, D. W., Rush, A. J., Fava, M., & Trivedi, M. H. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000000 · Cited by 59 · cited 3×
“Additionally, the obesity rate in this sample was higher than the national rates of obesity (Toups et al., 2013).”
BackgroundInfluentialSelf-citation
Cited by
Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression
Milaneschi, Y., Lamers, F., Berk, M., & Penninx, B. W. J. H. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.014 · Cited by 425
Grigolon, R. B., Trevizol, A. P., Gerchman, F., Bambokian, A. D., Magee, T., McIntyre, R. S., Gomes, F. A., Brietzke, E., & Mansur, R. B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.032 · Cited by 35
Boland, E. M., Vittengl, J. R., Clark, L. A., Thase, M. E., & Jarrett, R. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.10.033 · Cited by 29
Dale, R. M., Bryant, K. A., & Thompson, N. R. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001149 · Cited by 29
Puzhko, S., Schuster, T., Barnett, T. A., Renoux, C., Rosenberg, E., Barber, D., & Bartlett, G. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00024 · Cited by 7
Metadata
- Authors
- Jha, M. K., Wakhlu, S., Dronamraju, N., Minhajuddin, A., Greer, T. L., & Trivedi, M. H.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 234
- Pages
- 34-37
- ISSN
- 0165-0327 (ISSN-L)
- OpenAlex
- W2789957615
- Cited by
- 60
- References
- 9
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.